HIGHLIGHTS
- who: Yu Tang and colleagues from the University of Campania Luigi Vanvitelli, Italy have published the Article: Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC, in the Journal: (JOURNAL)
- what: The authors focused on patients with late-stage HR-positive/HER2-negative metastatic breast cancers who have received the 1st and 2nd line endocrine therapy previously, and used circulating tumor DNA to investigate the ET-resistant biomarkers and the therapeutic targets. In this study, tumor mutation burden (TMB, number of the somatic mutations per mega . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.